公开(公告)号：US20150087648A1

公开(公告)日：2015-03-26

申请号：US14537218

申请日：2014-11-10

申请人： SANOFI

发明人： Werngard CZECHTIZKY ,  John WESTON ,  Nils RACKELMANN ,  Michael PODESCHWA ,  Petra ARNDT ,  Klaus WIRTH ,  Heinz GOEGELEIN ,  Olaf RITZELER ,  Volker KRAFT ,  Patrice BELLEVERGUE ,  Gary McCORT

IPC分类号： C07D487/04 ,  C07D471/04 ,  C07D417/12 ,  C07D417/14

CPC分类号： C07D417/14 ,  A61K9/0019 ,  A61K47/10 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D513/04 ,  C07F9/65586

摘要： The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

摘要翻译： 本发明涉及式I的取代的2-（色满-6-基氧基） - 噻唑，其中Ar，R 2，R 3和R 4如权利要求中所定义。 式I的化合物是钠 - 钙交换剂（NCX）的抑制剂，特别是亚型1型（NCX1）的钠 - 钙交换剂的抑制剂，并且适用于治疗细胞内钙稳态受干扰的多种疾病，例如 作为心律失常，心力衰竭和中风。 本发明还涉及式I化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。

公开(公告)号：US20140243292A1

公开(公告)日：2014-08-28

申请号：US14204220

申请日：2014-03-11

申请人： Sanofi

发明人： Werngard CZECHTIZKY ,  John WESTON ,  Nils RACKELMANN ,  Michael PODESCHWA ,  Petra ARNDT ,  Klaus WIRTH ,  Heinz GOEGELEIN ,  Olaf RITZELER ,  Volker KRAFT ,  Patrice BELLEVERGUE ,  Gary McCORT

IPC分类号： C07D417/12 ,  C07F9/6553 ,  C07D417/14

CPC分类号： C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07F9/655345

摘要： The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

摘要翻译： 本发明涉及式I的取代的2-（色满-6-基氧基） - 噻唑，其中Ar，R 2，R 3和R 4如权利要求中所定义。 式I的化合物是钠 - 钙交换剂（NCX）的抑制剂，特别是亚型1型（NCX1）的钠 - 钙交换剂的抑制剂，并且适用于治疗细胞内钙稳态受干扰的多种疾病，例如 作为心律失常，心力衰竭和中风。 本发明还涉及式I化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。